Peregrine Pharmaceuticals (NASDAQ:PPHM)

my favorite and never disappointing red thumb

Peregrine is advancing two novel cancer drug candidates that, combined with its hybrid business model, present attractive risk-reward opportunities in our view. Lead candidate bavituximab (bavi') has recently endured negative news flow, increasing skepticism from investors but creating a potential buying opportunity

speculative tip from a random person

Looks like I got out from under that last badly-timed red thumb on Peregrine a little quicker than I thought. Am I setting myself up for another one? Part of me wants Peregrine to keep the lights on a few more years so that I can keep riding the waves back into score leadership, which was cruelly stolen from me. Another part of me just wants the company to die so I can stop giving myself migraines trying to follow their soap opera drug trials. I only have a limited amount of time and I need to spend most of it on trade grade stocks, not floating dust particles like Peregrine. Damn you, OCD.

I always seem to get crappy prices on this Caps "game". I bought the Bear Raid in Real ife in the $1.60s.
I had a limit order here on the Caps at 1.65 that never executed so I then placed a regular order when it was trading at 1.80 forever and the Caps started me off at 1.83. Whatever. I'll play it from 1.83 on the bear raid in the Caps and from the 1.60s (much better :-) ) in Real Life.

High Volume Breakout on 02/13/13

Perigrine has several exciting new drugs that will soon be moving into phase III approval.

Spike from the announced update on the Internal Review of Its Phase II Second-Line Non-Small Cell Lung Cancer Trial; The results of the extensive internal review indicate that discrepancies are isolated to the placebo and 1 mg/kg treatment arms of the trial and that there was no evidence of discrepancies in the 3 mg/kg treatment arm of the trial. The review was prompted by the discovery of vial coding discrepancies while preparing for an end of Phase II meeting with the FDA. The internal review included a thorough operational review of multiple third-party vendor operations at sites worldwide, testing of investigational product used in the trial, additional patient sample testing to determine drug levels and a review of immunogenicity testing results from the trial. The results of the extensive internal review indicate that discrepancies are isolated to the placebo and 1 mg/kg treatment arms of the trial and that there was no evidence of discrepancies in the 3 mg/kg treatment arm of the trial.

A speculator's dream date. This stock recently suffered a tremendous loss due to the negligent actions of a third party contractor. The speculation that this company's new cancer durg, now in phase III, will be successful still remains strong. The speculation is bolstered by the positive results of the phase II trial that shows their cancer drug helping people live twice as long as competitors drugs. People now buying into this stock at this historically low level are betting that the mixup between placebos and the actual drug in phase II resulted in a lower overall success rate of the drug fighting cancer and that positive phase III testing results will launch the price well beyond the $5.50 level it recently fell from. The investors that got burned holding on to shares near or at the $5.50 level may never come back, but new speculators with cooler heads and looking for a bargain will buy, hold and push this to newer highs.

Dead cat bounce. Bad management.

Not much insider trading lately but the most recent was a buy by a director. Charts look very bottomy as well.

approval of products

Data reported NOT RELIABLE.....this can just not happen to a biopharma company......

It has been hyped up and due to fall.

This is probably the last time I red thumb a company anywhere near $0.50. Although my pick is quickly approaching -400 points - by far my worst pick active or ever - I am sure the company will fall pretty far soon enough. If only I had followed zz's green thumb at the same entry point I could have enjoyed a swing of over 500 pts. $@!%! me

good product pipeline

Seems like a good opportunity to get into a stock that has a following at a bargain price...

biot

This is another long term stock. They have innovative treatments and have shown strong results. They are attacking diseases that not many others are after. This could very likely have an FDA approval in the next few years. If they don't have two.